Joshua Ruch
CIK 943431 · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RLOC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
EAST QUOGUE, NY 11942
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WGS | Director | 45,240 | $68.94 | $3.12M | $0 | 1 | 2026-06-23 |
| GeneDx Holdings Corp. (WGSWW) Delisted | Director | 56,381 | $0.00 | $11 | -$6.09M | 12 | 2025-11-26 |
| GeneDx Holdings Corp. (SMFRW) Delisted | Director | 179,486 | $0.02 | $4.3K | $0 | 6 | 2022-10-18 |
| NephroGenex, Inc. (NRX) Delisted | Director | 1,326,826 | — | — | $0 | 1 | 2014-02-19 |
| VERENIUM CORP (VRNM) Delisted | Director | 482,211 | — | — | $0 | 11 | 2013-06-25 |
| GENVEC INC (GNVC) Delisted | Director | 34,776 | — | — | $0 | 6 | 2010-06-18 |
| ReachLocal Inc (RLOC) Delisted | 10%+ Owner | 3,331,966 | — | — | $24.00M | 1 | 2010-05-25 |
| BFLY | Director | 8,823,529 | $7.10 | $62.65M | $0 | 1 | 2010-02-26 |
Recent Filings · Page 2 of 5
41 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-10-17 | GeneDx Holdings Corp. (WGSWW) Delisted | Exer (M) | +129 | $0 | EDGAR |
| 2023-07-25 | GeneDx Holdings Corp. (WGSWW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-04 | GeneDx Holdings Corp. (WGSWW) Delisted | Exer (M) | +45,454 | $0 | EDGAR |
| 2023-02-03 | GeneDx Holdings Corp. (WGSWW) Delisted | Grant (A) | +4,285,714 | $1.50M | EDGAR |
| 2022-10-18 | GeneDx Holdings Corp. (SMFRW) Delisted | Exer (M) | +4,278 | $0 | EDGAR |
| 2022-07-12 | GeneDx Holdings Corp. (SMFRW) Delisted | Grant (A) | +2,125,000 | $8.50M | EDGAR |
| 2022-05-12 | GeneDx Holdings Corp. (SMFRW) Delisted | Exer (M) | +12,836 | $0 | EDGAR |
| 2022-05-06 | GeneDx Holdings Corp. (SMFRW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-04 | GeneDx Holdings Corp. (SMFRW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-10-19 | GeneDx Holdings Corp. (SMFRW) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.